Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-07-01-Speech-2-154"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-07-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Strengthening the European pharmaceutical industry in the interest of patients – proposals for action2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20030701.6.2-154"2
lpv:hasSubsequent	lp_eu:2003-07-01-Speech-2-1552
lpv:speaker	lp:Liikanen2
lpv:spoken text	". Mr President, in reply to the first question, if there is real work on the new indications, which really means new innovations, then supplementary protection data exclusivity can be guaranteed. As far as efficiency factors are concerned, our position is that authorisation should be science-based but of course, once the authorities of the Member States decide which medicines they reimburse by public funds, they can reinforce that by different studies of their efficiency and that is supported also by G10. In that area G10 is proposing, and the Commission is supporting that proposal, that more exchanges of information on best practice and these kinds of efficiency studies could be undertaken in future. Regarding the second question, of course it is very much in the hands of Member States. There is very different legislation in Member States, whereby patients are being directed to use different solutions, either only the product which traditionally has been under patent or at the same time generics, when generics are inside the market. On the European level perhaps the emphasis is not there; it should be more on the national level."@en1
lpv:unclassifiedMetadata	"Commission"1 "Liikanen,"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph